XML 21 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Net revenues $ 15,846 $ 14,925 $ 15,878
Cost of sales 8,200 7,952 8,284
Gross profit 7,645 6,973 7,594
Research and development expenses, net 953 838 967
Selling and marketing expenses 2,336 2,265 2,429
General and administrative expenses 1,162 1,180 1,099
Intangible assets impairments 350 355 424
Goodwill impairment 700 2,045 0
Other asset impairments, restructuring and other items [1] 718 512 341
Legal settlements and loss contingencies 1,043 2,082 717
Other income (49) (107) (98)
Operating (loss) income [1] 433 (2,197) 1,716
Financial expenses – net 1,057 966 1,058
Income (loss) before income taxes [1],[2] (624) (3,163) 658
Income taxes (benefit) [2] (7) (643) 211
Share in (profits) losses of associated companies – net (2) (21) (9)
Net income (loss) (615) (2,499) 456
Net income (loss) attributable to non-controlling interests (56) (53) 39
Net income (loss) attributable to Teva $ (559) $ (2,446) $ 417
Earnings (loss) per share attributable to ordinary shareholders:      
Basic $ (0.5) $ (2.2) $ 0.38
Diluted $ (0.5) $ (2.2) $ 0.38
Weighted average number of shares (in millions):      
Basic 1,119 1,110 1,102
Diluted 1,119 1,110 1,107
[1] The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b.
[2] The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.